A research team co-led by scientists at the University of Arizona College of Medicine—Tucson found that an osteoporosis drug ...
Non-invasive therapeutics for anti-osteoporosis treatment and fracture healing are available in both oral and injectable ...
Celltrion’s two biosimilar treatments for treating osteoporosis and preventing bone metastasis complications in cancer ...
Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...
The FDA approved the denosumab biosimilar Ospomyv, interchangeable with Prolia, for preventing osteoporosis-related fracture ...
An FDA-approved osteoporosis treatment might nudge a mutated protein back into shape and improve heart function, according to ...
The Osteoporosis Society of the Philippines Foundation Inc. (OSPFI) estimates that by 2050, around 10.2 million Filipinos ...
Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis ...
A new case report was published in Oncoscience's Volume 12 on February 4, 2025, titled “Breaking point: Systemic mastocytosis manifesting as severe osteoporosis.” ...
Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™)
Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCE™ (60mg pre-filled syringe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback